[Ventilator-associated pneumonia and multiresistant bacteria]
- PMID: 17309020
- DOI: 10.1055/s-2007-971164
[Ventilator-associated pneumonia and multiresistant bacteria]
Abstract
Ventilator-associated pneumonia remains the most serious nosocomial infection in critically ill patients. Providing appropriate antibiotic therapy promptly is crucial for successful treatment; whereas the diagnostic approach seems to play a minor role. The empirical antibiotic therapy should be guided by the risk for infections due to multiresistant bacteria. For patients at risk a combination therapy, considering local resistance data and formerly applied antibiotic substances, is recommended. Reevaluation and deescalation of antibiotic therapy based on microbiological culture results and discontinuation of antimicrobial treatment after one week is essential for the control of broadspectrum antibiotic use and antibiotic resistance.
Similar articles
-
When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn?Semin Respir Infect. 2003 Jun;18(2):122-8. Semin Respir Infect. 2003. PMID: 12840793 Review.
-
Therapy for ventilator-associated pneumonia: what works, what doesn't.Respir Care Clin N Am. 2004 Sep;10(3):341-58, vi. doi: 10.1016/j.rcc.2004.04.004. Respir Care Clin N Am. 2004. PMID: 15458732 Review.
-
[Epidemiology and antibiotic therapy in nosocomial pneumonia].Rev Pneumol Clin. 2001 Apr;57(2):132-8. Rev Pneumol Clin. 2001. PMID: 11353919 Review. French.
-
[Antibiotic strategies in the treatment of infection in critically ill patients].Ugeskr Laeger. 2007 Feb 19;169(8):699-702. Ugeskr Laeger. 2007. PMID: 17313920 Review. Danish.
-
Optimizing antibiotic treatment for ventilator-associated pneumonia.Pharmacotherapy. 2006 Feb;26(2):204-13. doi: 10.1592/phco.26.2.204. Pharmacotherapy. 2006. PMID: 16466325 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical